Trial Profile

Comparison of Neurotoxic Potential of Abraxane versus Oxaliplatin and Paclitaxel chemotherapy in cancer patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Oxaliplatin
Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

25 Mar 2022 Status changed from recruiting to completed.
11 Aug 2016 Status changed from not yet recruiting to recruiting.
30 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com